Welcome to our dedicated page for Myomo SEC filings (Ticker: MYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Myomo Inc. filings document material events for a Delaware medical-device company focused on wearable robotics and the MyoPro powered upper-limb orthosis. Recent Form 8-K disclosures furnish quarterly and annual operating results, revenue sources, MyoPro orders and authorizations, patient-pipeline activity, and exhibits tied to financial press releases.
The filing record also covers governance and capital-structure matters, including board appointments, director compensation arrangements, indemnification agreements, and loan and security agreements. These disclosures describe formal reporting of operating performance, financing terms, corporate governance actions and related risk and control subjects for MYO.
Myomo, Inc. (MYO) – Form 4 filing: Chief Financial Officer David A. Henry reported a Code “F” transaction on 30 June 2025, in which 23,587 shares of common stock were withheld and sold at $2.19 per share solely to satisfy income-tax obligations arising from the vesting of restricted stock units (RSUs) on 28 June 2025. After the automatic sale, the executive continues to hold 427,900 shares in direct ownership. No derivative security activity was reported, and the filing discloses no additional purchases or open-market sales. Such tax-withholding dispositions are routine and generally neutral with respect to the executive’s long-term ownership position and the company’s fundamentals.
Myomo, Inc. (MYO) – Form 144 filing: The notice discloses a proposed sale of 23,587 common shares by David Henry through Morgan Stanley, targeted for 30 June 2025 on the NYSE American. The shares have an aggregate market value of $51,655.53, equating to roughly 0.07 % of the company’s 35,978,922 shares outstanding, indicating an immaterial proportion of total equity.
The securities derive from the vesting of restricted stock units (RSUs) on 28 June 2025, when 65,000 shares were acquired from Myomo. In addition, the filer sold 8,373 shares on 06 June 2025 for gross proceeds of $24,867.81. No other financial data or operational commentary is provided in the filing.
Because the planned sale represents a very small percentage of outstanding shares and does not involve new share issuance, dilution is not a concern. Nonetheless, investors often monitor insider transactions for sentiment signals; repeated insider selling can be interpreted cautiously, even when associated with equity compensation events such as RSU vesting.